Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04388176
Other study ID # VP-C21-004
Secondary ID 2019-003203-35
Status Completed
Phase Phase 2
First received
Last updated
Start date January 3, 2020
Est. completion date December 14, 2020

Study information

Verified date July 2022
Source Vicore Pharma AB
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomised, double-blind, placebo-controlled, cross-over phase 2 trial investigating the effect of C21 on cold-induced vasoconstriction in subjects with Raynaud's phenomenon secondary to systemic sclerosis. The purpose of the trial is to achieve a vasodilatory effect in subjects with Raynaud's phenomenon by stimulation of the AT2R (angiotensin II type 2 receptor) with C21.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date December 14, 2020
Est. primary completion date December 14, 2020
Accepts healthy volunteers No
Gender All
Age group 19 Years to 75 Years
Eligibility Inclusion Criteria: 1. Written informed consent must be obtained before any trial related procedures are performed. 2. Subjects diagnosed with SSc according to European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria 3. Age 19-75 years inclusive 4. RP secondary to SSc as determined by the investigator, and with a typical frequency of attacks during the winter months (November-March) of on average at least 5 per week. Exclusion Criteria: 1. Smoking (including E-cigarettes) or use of nicotine replacement therapy for three months prior to Visit 1 and during the trial. 2. BMI >30 3. Mixed connective tissue disease or "overlap" (i.e. those who satisfy more than one set of ACR criteria for a rheumatic disease). 4. Concurrent serious medical condition with special attention to cardiac or ophthalmic conditions which in the opinion of the investigator makes the patient inappropriate for this study 5. Malignancy within the past 5 years with the exception of in situ removal of basal cell carcinoma and cervical intraepithelial neoplasia grade I 6. Planned major surgery within the duration of the study 7. Subjects who forsake any alcohol intake or have known uncontrolled allergic conditions or allergy/hypersensitivity to any components of the trial drug or placebo excipients (see Section 7.1) 8. Blood donation (or corresponding blood loss) within three months prior to Visit 1 9. Treatment with any of the medications listed below within 4 weeks prior to Visit 1: - Any dose-change or initiation of vasoactive substances , and not able or willing to withhold these medications for 3 days preceding Visit 2 and Visit 3, respectively - Iloprost - Any treatment with CYP3A4 inducers (e.g. rifampicin, phenytoin, St John's Wort) - Any treatment with CYP3A4 inhibitors (e.g. clarithromycin, ketoconazole, nefazodone, itraconazole, ritonavir) - Any treatment with medicines that are substrates of CYP1A2, CYP3A4 or CYP2C9 with a narrow therapeutic range - Any experimental drug - Any systemic immunosuppressive therapy other than: - Inhaled corticosteroids which can be used throughout the trial period - The continuation of stable doses of <10 mg prednisolone - Mycophenolate mofetil (MMF) which must be withheld for 3 days preceding Visit 2 and Visit 3 10. Any of the following findings at the time of screening: - Finger temperature below 27°C after acclimatising at an ambient temperature of 23°C for a period of 20 minutes - Prolonged QTcF (>450 ms), cardiac arrhythmias or any clinically significant abnormalities in the resting ECG, as judged by the Investigator - Positive results for HBsAg, HCVAb or HIV 1+2 Ag/Ab - Positive serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) - Clinically significant abnormal laboratory value at Visit 1 indicating a potential risk for the subject if enrolled in the trial as evaluated by the Investigator 11. Pregnant or breast-feeding female subjects. 12. Female subjects of childbearing potential not willing to use contraceptive methods described in Section 5.3.1. 13. Male subjects not willing to use contraceptive methods described in Section 5.3.1. 14. Participation in any other interventional trial during the trial period 15. Subjects known or suspected of not being able to comply with this trial protocol (e.g. due to alcoholism, drug dependency or psychological disorder)

Study Design


Intervention

Drug:
C21
C21 as first treatment
C21
C21 as second treatment
Placebo
Placebo as second treatment
Placebo
Placebo as first treatment

Locations

Country Name City State
United Kingdom Department of Rheumatology, Salford Royal Hospital Manchester Salford

Sponsors (2)

Lead Sponsor Collaborator
Vicore Pharma AB SGS Life Sciences, a division of SGS Belgium NV

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in Finger Temperature From Intake of IMP to Start of Cold Challenge From intake of IMP to start of cold challenge (0-40 min)
Other Nailfold Capillaroscopy (Including Red Blood Cell Velocity Measurements) Nailfold capillaroscopy mean velocity was measured as red blood cell velocity before cold challenge and post recovery Before cold challenge (at 40 min) and post-recovery (at 55 min)
Primary Area Under the Curve for Rewarming of Each Finger After Cold Challenge (AUC) as Measured by Thermography Area under the curve for rewarming of each finger after cold challenge as measured by thermography for 15 min For 15 min after cold challenge (40-55 min after IMP [investigational manufacturing product] administration)
Secondary Maximum Skin Temperature After Rewarming (MAX) Maximum skin temperature after rewarming within 15 min after cold challenge For 15 min after cold challenge (40-55 min after IMP administration)
Secondary The Distal Dorsal Difference, Defined as the Difference in Temperature Between the Dorsum and the Finger (DDD) The distal dorsal difference, defined as the difference in temperature between the dorsum and the finger (DDD), from administration of IMP until before cold challenge (0 to 40 min) Baseline, 10, 20, 30 and 40 min
Secondary Gradient of Rewarming in the First 2 Minutes Post-cold Challenge (GRAD) 2 min after cold challenge (40-42 min after IMP administration)
See also
  Status Clinical Trial Phase
Completed NCT03274076 - Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) Phase 1/Phase 2
Completed NCT04300426 - Safety and Efficacy of Anaerobic Cultivated Human Intestinal Microbiome Transplantation in Systemic Sclerosis (ReSScue) Phase 2
Recruiting NCT06058091 - RY_SW01 Cell Injection Therapy in Systemic Sclerosis Phase 1/Phase 2
Recruiting NCT04356755 - Subcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma. Phase 2
Suspended NCT06210945 - Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis Phase 2
Not yet recruiting NCT05947682 - Manufacturing of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells for Treatment of Severe Systemic Sclerosis N/A
Not yet recruiting NCT04303208 - Sirtuin 3 and Sirtuin 7 in Systemic Sclerosis N/A
Not yet recruiting NCT05177380 - Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis N/A
Recruiting NCT02551042 - CSL Behring Sclero XIII Phase 2
Terminated NCT02243111 - Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound N/A
Terminated NCT02246348 - Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc) N/A
Completed NCT01933334 - Safety and Tolerability of Pirfenidone in Patients With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS) Phase 2
Completed NCT01468792 - Hemodynamic Changes in Connective Tissue Disease N/A
Terminated NCT00848107 - Open-Label Study of Oral Treprostinil in Digital Ulcers Phase 2
Completed NCT00984932 - Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension Phase 3
Completed NCT00074568 - Scleroderma Registry
Not yet recruiting NCT06412614 - Evaluation of Patients With Systemic Sclerosis Without Specific or Associated Autoantibodies
Terminated NCT00622687 - Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis Phase 2
Recruiting NCT04464434 - Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis Phase 4
Recruiting NCT04246528 - SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF) N/A